WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory
GlaxoSmithKlineGSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

www.gsk.com

GlaxoSmithKline RSS Channel

Filters
List of articles in category GlaxoSmithKline
Title Published Date
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China 15 June 2011
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine) 13 June 2011
Millions of children in the world's poorest countries could receive vaccination against rotavirus diarrhoeal disease 09 June 2011
GSK forms partnership with three leading NGOs 25 May 2011
Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research 12 May 2011
GSK welcomes key agreement to support global preparedness against pandemic influenza 19 April 2011
GSK publishes payments for research, consulting and advising by US healthcare professionals 01 April 2011
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction 28 March 2011
GSK supports recovery efforts to help those affected by the Japan earthquake 20 March 2011
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson's disease 15 March 2011
  • Start
  • Prev
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next
  • End
Health data interoperability: Opportunities and threats

Business & Industry

  • Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
  • Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
  • Amgen successfully completes acquisition of Five Prime Therapeutics
  • GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
  • Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Research & Development

  • Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
  • Patients who are obese or overweight are at risk for a more severe course of COVID-19
  • New COVID-19 vaccine may offer broad protection from coronaviruses
  • SARS-CoV-2: New findings on the persistence of neutralizing antibodies
  • Massive fragment screen points way to new SARS-CoV-2 inhibitors
  • B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
  • COVID-19 causes 'unexpected' cellular response in the lungs

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
  • Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
  • AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
  • EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
  1. You are here:  
  2. Home
  3. GlaxoSmithKline
  4. GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.